All lobbying filings

The Procter and Gamble Company

The Procter and Gamble Company filed a Q3 report for The Procter and Gamble Company on October 22, 2025.

Lobbying for The Procter and Gamble Company

As filed: THE PROCTER AND GAMBLE COMPANY for THE PROCTER AND GAMBLE COMPANY.

All filings by The Procter and Gamble Company · Everything The Procter and Gamble Company has reported

Filing · LD-2 quarterly report Q3 report

Reporting period

3rd Quarter 2025

July 1 - Sep 30 · Posted Oct 22, 2025

Expenses

$751,000

What this organization spent lobbying with its own staff. Reported using IRS section 162(e) definitions (method C): the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.

Client based in

District of Columbia

Official filing document

Government bodies contacted 3

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 9

Pharmacy

-Issues related to FDA review of active ingredients in over-the-counter products

Health Issues

-H.R.4273: Over-the-Counter Monograph Drug User Fee Amendments (Entire Bill)

Chemicals/Chemical Industry

-Issues related to Toxic Substances Control Act reform (No Bill)

Environment/Superfund

-Issues related to plastics recycling (No Bill)

Taxation/Internal Revenue Code

-OECD Digital Tax Project (Global Minimum Tax Implementation) -Implementation of H.R. 1 (One Big Beautiful Bill - Corporate/International Tax Provisions) -S.2003 (Strengthening Benefit Plans Act of 2025) -H.R. 1 (One Big Beautiful Bill Act - Corporate/International Tax Provisions)

Trade (domestic/foreign)

-Issues related to IEEPA Reciprocal Tariffs -Issues related to Softwood Lumber 232 Trade Investigation -Issues related to America First Trade Policy -Issues related to tariffs (232 Pharmaceuticals)

Trucking/Shipping

-Issues Related to Gross Vehicle Weight Limits (no bill)

Foreign Relations

-Issues related to Asia-Pacific Economic Cooperation (APEC) -Issues related to Middle East (Syria US export controls) -Issues related to Latin America

Consumer Issues/Safety/Products

-Issues related to product safety

Bills named in this filing 3

H.R. 4273
Over-the-Counter Monograph Drug User Fee Amendments
H.R. 1
One Big Beautiful Bill Act
S. 2003
Strengthening Benefit Plans Act of 2025

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.